Loomis, Sayles & Company
ACHN

Loomis, Sayles & Company’s Achillion Pharmaceuticals ACHN Stock Holding History

Loomis, Sayles & Company’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-788
Closed -$3K – 1020
2017
Q1 		$3K Hold
788
– – ﹤0.01% 920
2016
Q4 		$3K Sell
788
-628
-44% -$3.34K ﹤0.01% 964
2016
Q3 		$11K Hold
1,416
– – ﹤0.01% 757
2016
Q2 		$11K Buy
+1,416
New +$12.1K ﹤0.01% 742

Other funds holding ACHN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Loomis, Sayles & Company's ACHN Position: Q2 2017 in Review

Loomis, Sayles & Company sold out of Achillion Pharmaceuticals (ACHN) in Q2 2017, closing a stake of 788 shares — an estimated $3K sold.

Loomis, Sayles & Company first reported a position in ACHN in Q2 2016 and held it in 4 quarters. The position peaked at $11K in Q3 2016. 129 funds tracked by Wall St. Rank hold ACHN as of Q2 2017.

  • Loomis, Sayles & Company reported no remaining Achillion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Loomis, Sayles & Company sold 788 Achillion Pharmaceuticals shares in Q2 2017, an estimated $3K.
  • Loomis, Sayles & Company first reported a position in Achillion Pharmaceuticals in Q2 2016 and held it in 4 quarters.
  • Loomis, Sayles & Company's Achillion Pharmaceuticals position peaked at $11K in Q3 2016.
  • 129 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q2 2017.

Based on Loomis, Sayles & Company's 13F filing for Q2 2017, filed 14 Aug 2017.